依达拉奉治疗急性脑梗死疗效观察

Clinical evaluation of edaravone for treatment of acute cerebral infarction

目的观察依达拉奉治疗急性脑梗死的疗效和安全性。方法将70例急性脑梗死患者随机分成治疗组和对照组,每组35例。2组均予常规治疗。在此基础上,对照组应用丹参注射液20 mL加入250 mL生理氯化钠溶液,静脉滴注,每日1次;治疗组应用依达拉奉注射液30 mg加入250 mL生理氯化钠溶液中,静脉滴注,每日2次。2组均以14 d为1个疗程。采用治疗前后神经功能缺失评分结果对2组患者疗效进行评估。结果治疗前,治疗组神经功能缺失评分与对照组比较无差异(P>0.05);治疗7 d,2组神经功能缺失评分比较有差异(P<0.05);治疗28 d,2组有显著性差异(P<0.01)。治疗组有效率(85.71%)明显高于对照组(62.86%)(P<0.05)。治疗过程中无任何不良反应发生。结论依达拉奉治疗急性脑梗死是安全有效的。

Objective To evaluate the efficacy and safety of edaravone in the treatment of acute cerebral infarction （ACI）. Methods Seventy patients with ACI were randomly divided into treatment group and control group. There were 35 cases in each group. Two groups were given regular treatment,and control group received 20 mL danshiton injection by adding 250 mL normal saline with intravenous drip, once a day. Treatment group received 30 mg edaravone by adding 250 mL normal saline, 2 times per day. The therapy cycle was 14 days in 2 groups. The efficacy was assessed by the neurological functional deficit scores before and after treatment. Results Compared with control group, treatment group initiated the significant improvements in neurofunctions in day 7 after the treatment （ P 〈 0.05 ）, and showed significant difference of neurofunctions in day 28 after the treatment （ P 〈 0.01 ）. The efficacy rate of treatment group was higher than that of control group. There was no adverse effect during the process of treatment. Conclusion Edaravone is safe and effective in the treatment of ACI.